Contact
Please use this form to send email to PR contact of this press release:
InterveXion Enrolls First Patient in Meth-OD, a Phase 2 Study of IXT-m200 in Methamphetamine Overdose
TO:
Misty Stevens
InterveXion Therapeutics
+1 501-554-2377